Taxanes in hormone-refractory prostate cancer

Cancer Practice

Volumn 7, Issue 5, 1999, Pages 270-272

  Kang, Min H ^a   Figg, William D ^a   Dahut, William ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; PACLITAXEL; TAXANE DERIVATIVE;

ABSCESS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; FATIGUE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS POTENTIAL; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SMALL INTESTINE OBSTRUCTION; STOMATITIS;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HORMONES; HUMANS; MALE; PACLITAXEL; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 0032848931     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.1999.75005.x     Document Type: Review

References (19)

1. Tannock IF. If there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate. J Clin Oncol. 1985; 3:1013-1021.
2. Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol. 1988;15:371-389.
3. Scher HI, Kelly W, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 1999;91: 244-251.
4. Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72: 2457-2460.
5. Nemeth JA, Trivedi C, Barroso U Jr. Dose-intense paclitaxel in prostate cancer: Preclinical and clinical feasibility and antitumor activity. J Urol. 1999;161(suppl):1138.
6. Friedland D, Cohen J, Miller R. A phase II trial of taxotere in hormone refractory prostate cancer. Proc ASCO. 1999;18: 1237.
7. Picus J, Schultz M, Cochrane J, et al. A phase II trial of docetaxel in patients with hormone refractory prostate cancer (HRPC): long term results. Proc ASCO. 1999;18:1206.
8. Hudes GR, Nathan F, Khater C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol. 1995;22(suppl 12):41-45.
9. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997;15: 3156-3163.
10. Petrylak DP, Macarther RB, O'Corner J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958-967.
11. Kreis W, Budman DR, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999;10:33-38.
12. Sinibaldi VJ, Carducci MA, Moore-Cooper S. A phase II study evaluating a one day course of estramustine phosphate and docetaxel in patients with hormone refractory prostate cancer. Proc ASCO. 1999;18:1239.
13. Haas N, Garay C, Roth B. Weekly paclitaxel by 3-hour infusion plus oral estramustine in metastatic hormone refractory prostate cancer. Proc ASCO. 1999;18:1311.
14. Leitner SP, Scoppetuelo M, Kanowitz JM. Phase II trial of weekly one hour paclitaxel plus oral estramustine taken the day before, of, and after paclitaxel in patients with metastatic hormone refractory prostate cancer. Proc ASCO. 1999;18: 1331.
15. Natale RB, Zaretsky SL. Phase I/II trial of estramustine and taxotere in patients with metastatic hormone-refractory prostate cancer. Proc ASCO. 1999;18:1343.
16. Weitzman A, Shelton G, Zuech N. Phase II study of estramustine combined with docetaxel in patients with androgen-independent prostate cancer. Proc ASCO. 1999;18:1369.
17. Savarese DM, Taplin M, Marchesami B. A phase II study of docetaxel, estramustine and low dose hydrocortisone in hormone refractory prostate cancen CALGB 9780. Proc ASCO. 1999;18:1234.
18. Pienta KJ, Smith DC. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractoryprostate cancer. Semin Oncol. 1997;24(suppl 15):S15-72-S15-77.
19. Kelly K, Gaudin P, Slovin S. Paclitaxel, estramustine and carboplatin in patients with advanced prostate cancer. J Urol. 1999;161(suppl):683.